Catalyst Pharmaceuticals Stock News

The average of price targets set by Wall Street analysts indicates a potential upside of 29.6% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the posit

Analysts expect Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to report $0.11 earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Catalyst Pharmaceuticals earnings. The highest EPS estimate is $0.11 and the lowest is $0.10. Catalyst Pharmaceuticals also reported earnings per share of $0.11 in the same quarter last year. []

Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q3 2021 Results - Earnings Call Transcript

Catalyst's (CPRX) earnings meet estimates in the third quarter of 2021 while revenues beat the same.

Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry players' third-quarter results. XNCR, ENTA, CPRX and MTEM may prove to be good additions to one's portfolio.

The Company will host a Conference Call and Webcast on November 10, 2021, at 8:30 AM EST The Company will host a Conference Call and Webcast on November 10, 2021, at 8:30 AM EST

Hint: it doesn't really matter what kind of market it is.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Catalyst (CPRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price

Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) shares are trading higher Wednesday although there looks to be no company-evident news to explain the jump in price. The stock is trading on above-average v

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has received a favorable decision from the 11th Circuit Court of Appeals in its appeal to overturn a District Court decision upholding the FDA approval o

CORAL GABLES, Fla., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,

Selecting U.S.-listed equities that have the characteristics listed below represents a solid starting point when in search of potential value opportunities, in my opinion:

CORAL GABLES, Fla., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,

CORAL GABLES, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,